



## **Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference**

March 2, 2026

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET.

A live webcast can be accessed under "Events & Presentations" in the Investors & Media section of the Xilio Therapeutics website at [ir.xiliotx.com](http://ir.xiliotx.com). A replay of the webcast will be archived on the website for 30 days following the presentation.

### **About Xilio Therapeutics**

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting [www.xiliotx.com](http://www.xiliotx.com) and follow us on LinkedIn ([Xilio Therapeutics, Inc.](https://www.linkedin.com/company/xilio-therapeutics)).

### **Investor Contact**

Alex Lobo, Precision AQ  
[alex.lobo@precisionaq.com](mailto:alex.lobo@precisionaq.com)

### **Media Contact**

Josie Butler, 1AB  
[josie@1abmedia.com](mailto:josie@1abmedia.com)